Because it is not feasible to evaluate IGF2 disorders (a kind of carcinogenic driver) by detecting tumor mutations alone, scRNA-seq of CTC is an excellent tool for detecting non-mutable drug-related gene abnormalities, such as IGF2 overexpression (28). Here, IGF2 is linked to neoplasm.